• EN
  • Suche

Portfoliounternehmen: Kapitalerhöhung Sensimed SA

Sensimed SA Raises 17 Million CHF in Series C Financing

Sensimed AG, a portfolio company of New Value AG, announced today the first closing of its Series C financing round. The first closing at CHF 17m was completed by current shareholders, the Sandoz Family Foundation, ELM Development, and successful entrepreneurs in the medical devices industry.
(paprico is advising the investment company New Value AG in its investment in Sensimed SA).

Sensimed AG has developed a non-invasive soft contact lens-based solution, the SENSIMED Triggerfish® that revolutionizes glaucoma management by providing continuous 24-hour intraocular pressure (IOP) profiles as well as modeling and analysis of IOP patterns. The 24-hour IOP profiles, centralized on a registry together with patient and treatment information, are processed by powerful modeling and learning algorithms identifying pathological patterns that can be used to differentiate indication and to personalize treatment. Sensimed is directly positioned at the convergence between devices, treatment and information. The company believes that this global knowledge-building approach will enable ophthalmologists to better improve management of patients with potentially progressive glaucomatous disease.

Funds will be used to finalize approval in the US and in China, to extend the commercialization currently restricted to leading centers in about twenty countries to a larger geography, to continue a wide-spectrum of post-marketing application trials, to implement and open the central registry to all users, and to fund on-going operations. “This round of financing follows major breakthroughs in the understanding of 24-hour patterns which broaden significantly the commercial application of our technology,” says Sensimed CEO Jean-Marc Wismer. “It will also enable us to bring those new findings to the market to help doctors better diagnose, discriminate and treat various glaucomatous indication.

Veröffentlicht:25.10.2012
Link:www.sensimed.ch
(324 Worte)

Über paprico 

paprico – partners for private capital & companies – ist eine Spezialistin für unternehmerische Direktbeteiligungen im Private Equity und Venture Capital Markt der Schweiz und dem deutschsprachigen Raum. 

Wir zeichnen uns aus durch ein klar umrissenes Leistungsangebot für Unternehmer und Family Offices sowie für private und institutionelle Investoren.